Teva- Pharmaceutical Industries Profit Margin

The latest profit margin for TEVA is 4.08% as of June 2026. That compares with -0.95% in the prior-year period — up 529.1% year over year. That is below the Healthcare sector average of 14.41%. Investors often review this figure alongside Teva- Pharmaceutical Industries's historical trend and sector peers before judging valuation or financial health.

Over the past year, TEVA's profit margin moved from -0.95% to 4.08% — a 529.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Teva- Pharmaceutical Industries's valuation or profitability profile.

Against Healthcare companies, TEVA currently prints 4.08% for profit margin, while the sector average sits near 14.41%. That is roughly 71.7% below the sector mean. Large gaps often invite a closer look at Teva- Pharmaceutical Industries's growth, margins, and balance sheet.

Profit Margin shows how effectively Teva- Pharmaceutical Industries converts resources into returns. At 4.08%, TEVA may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -0.95% in the prior-year period — up 529.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting TEVA's profit margin (4.08%), review year-over-year change from -0.95%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.